Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (2566.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$5.24 (-1.41%) as of
Key statistics
- Market cap
- 1.24B
- P/E (TTM)
- 8.32
- EPS (TTM)
- 0.630
- Dividend yield
- 1.23%
- 52-week range
- 4.600 – 10.840
- Revenue (TTM)
- 1.3B
- Profit margin
- 10.74%
- Volume
- 11.40k
About Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of biopharmaceutical products and medical devices in Mainland China and internationally. The company offers Guyoudao, a bone repair material; Jilifen, a human granulocyte colony stimulating factor injection; Jijufen, a human interleukin-11 injection; Jiouting, a palonosetron hydrochloride injection; Jifuwei, a fulvestrant injection; Jitansu, a fosaprepitant dimeglumine injection; and Jixinfen, PEG-GCSF injection. It also provides Jilixin avatrombopag maleate tablets; Jipailin, a low molecular weight heparin sodium injection; and Yinuojia, an enoxaparin sodium injection. The company was formerly known as Hangzhou Jiuyuan Gene Engineering Co., Ltd. and changed its name to Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. in April 2025. Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. was incorporated in 1993 and is headquartered in Hangzhou, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Hangzhou, China
- Employees
- 1,787
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.